View Post

Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA® (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer

In Clinical Trials by Barbara Jacoby

From: PR Newswire Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Oncologie’s investigational drug Bavituximab, an antibody that blocks the activity of phosphatidylserine (PS), and Merck’s anti-PD-1 therapy, …

View Post

Upcoming Phase 2 Trial Will Test Opdivo-MTG201 Combo for Malignant Pleural Mesothelioma

In Clinical Trials by Barbara Jacoby

By: Patricia Inacio, PhD From: immuno-oncologynews.com An upcoming Phase 2 trial will explore the safety and effectiveness of a combo therapy — Opdivo (nivolumab) and MTG201 – for the treatment of malignant pleural mesothelioma. The trial will soon be looking for participants who received prior chemotherapy. Mesothelioma is a rare type of cancer, commonly linked to exposure to asbestos, that …

View Post

Where Does T-DM1 Fit In First-Line Treatment for HER2-Positive Breast Cancer?

In Clinical Trials by Barbara Jacoby

By: Dave Levitan From: www.cancernetwork.com Trastuzumab emtansine (T-DM1) with or without pertuzumab yielded good overall survival in patients with HER2-positive metastatic breast cancer according to the results of a phase III trial published in Cancer. Though these were not superior to survival seen with taxane-based therapy, T-DM1 should be considered an option for first-line therapy in patients deemed unsuitable for …

View Post

Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

In Clinical Trials by Barbara Jacoby

From: PR Newswire – Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors – First-in-class investigational therapy using autologous CAR-T cells targeting advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to …

View Post

Newer Treatments and Combinations Emerging for Breast Cancer Brain Metastases

In Clinical Trials by Barbara Jacoby

By: Dylann Cohn-Emery From: targetedonc.com Multiple treatment options are emerging for patients with breast cancer that has metastasized to the brain, looking to improve upon the standards of care for patients with breast cancer–related brain metastases (BM) across breast cancer subtypes. A phase II study looking at abemaciclib (Verzenio), a CDK4/6 inhibitor, in patients with HR-positive, HER2-negative metastatic breast cancer …

View Post

Keytruda Plus Chemo Shows High Response Rate in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: specialtypharmacytimes.com Pembrolizumab (Keytruda, Merck) plus chemotherapy demonstrated a statistically significant improvement in pathological complete response rate (pCR) as a neoadjuvant therapy in patients with triple-negative breast cancer (TNBC), according to new data from a phase 3 study. Approximately 15% to 20% of patients with breast cancer are diagnosed with TNBC, which can be more difficult to treat than other …

View Post

Amgen Plans Pivotal Lung Cancer Trial For Its Pipeline Star

In Clinical Trials by Barbara Jacoby

Source: Andrew Dunn, BiotechDive From: pharmavoice.com Amgen stole the show at this year’s annual meeting of the American Society of Clinical Oncology with promising early data from a cancer drug designed to target KRAS mutations, an elusive target that’s frustrated decades of research efforts. Now, the biotech plans to soon advance the drug into a Phase 2 study in lung …

View Post

Inivata to Test Liquid Biopsy Against Tissue Sequencing in French Prospective Clinical Trial

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Liquid biopsy firm Inivata said today that it is launching a prospective clinical study with France’s Centre Léon Bérard cancer center to test whether its InVisionFirst-Lung test can get patients on appropriate treatment more quickly than tissue-based genetic testing. The randomized Phase III interventional trial is called LIquid Biopsy for the Early detection of LUng …

View Post

Merck Data Are Another Step for Immunotherapy in Breast Cancer

In Clinical Trials by Barbara Jacoby

From: xconomy.com Merck this morning announced that a combination of its drug pembrolizumab (Keytruda) and chemotherapy succeeded in a Phase 3 study in breast cancer, a potentially notable advance for immunotherapy in treating the disease. Merck (NYSE: MRK) said that Keytruda and chemotherapy beat chemo alone when given to patients with triple-negative breast cancer in a study called Keynote-522. The …

View Post

Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations

In Clinical Trials by Barbara Jacoby

From: mdanderson.org FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, according to an international Phase II trial led by The University of …